These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25131061)

  • 41. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
    Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.
    Miuma S; Ichikawa T; Miyaaki H; Haraguchi M; Tamada Y; Shibata H; Taura N; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
    J Interferon Cytokine Res; 2016 Jun; 36(6):358-66. PubMed ID: 27243278
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
    Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
    Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
    Berenguer M; Ortíz-Cantó C; Abellán JJ; Aguilera V; Rubín A; Prieto M; López-Labrador FX
    J Clin Virol; 2012 Mar; 53(3):231-8. PubMed ID: 22222052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Peytavin G; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2013 Oct; 27(16):2655-7. PubMed ID: 23939241
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
    Stanca CM; Fiel MI; Kontorinis N; Agarwal K; Emre S; Schiano TD
    Transplantation; 2007 Jul; 84(2):180-6. PubMed ID: 17667809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
    Satapathy SK; Fiel MI; Vanatta JM; Del Rio Martin J; Schiano TD
    Exp Clin Transplant; 2013 Dec; 11(6):522-9. PubMed ID: 23901801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of recurrent hepatitis C.
    Gane E
    Liver Transpl; 2002 Oct; 8(10 Suppl 1):S28-37. PubMed ID: 12362295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
    Jiménez-Méndez R; Castañeda-Hernández G
    Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin].
    Iferkhass S; Elasri F; Chatioui S; Khoyaali A; Bargach T; Reda K; Oubaaz A
    J Fr Ophtalmol; 2015 Jan; 38(1):34-40. PubMed ID: 25533994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiviral therapy in chronic hepatitis E: a systematic review.
    Peters van Ton AM; Gevers TJ; Drenth JP
    J Viral Hepat; 2015 Dec; 22(12):965-73. PubMed ID: 25760481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients.
    Oton E; Barcena R; Garcia-Garzon S; Moreno-Zamora A; Moreno A; Garcia-Gonzalez M; Blesa C; Foruny JR; Ruiz P
    Transplant Proc; 2005 Nov; 37(9):3963-4. PubMed ID: 16386597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.
    Kontorinis N; Agarwal K; Elhajj N; Fiel MI; Schiano TD
    Liver Transpl; 2006 May; 12(5):827-30. PubMed ID: 16628699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
    Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
    Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are viral or host factors predictive of response to interferon-ribavirin in transplant patients with hepatitis C?
    Roche B; Samuel D
    J Hepatol; 2010 May; 52(5):630-2. PubMed ID: 20334948
    [No Abstract]   [Full Text] [Related]  

  • 59. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.
    Bruchfeld A; Lindahl K; Reichard O; Carlsson T; Schvarcz R
    J Viral Hepat; 2006 May; 13(5):316-21. PubMed ID: 16637862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
    Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.